Drug Profile
Research programme: dopamine D2 receptor antagonists - Pierre Fabre
Latest Information Update: 14 Dec 2006
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 10 Jul 2001 No-Development-Reported for Psychotic disorders in France (Unknown route)
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
- 21 Oct 1998 New profile